Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative, antibody to hepatitis B core antigen (anti-HBc)-positive patients after allogeneic hematopoietic stem cell transplantation (HSCT) has not been prospectively studied. HBsAg-negative, anti-HBc-positive patients with undetectable HBV DNA undergoing allogeneic HSCT were prospectively monitored every 4 weeks. The primary endpoint was HBV reactivation, defined as detectable HBV DNA (10 IU/mL). Secondary endpoints included overall survival, HBsAg positivity, and changes in liver biochemistry and antibody to HBsAg levels. Among 297 allogeneic HSCT recipients, 85 (28.7%) were HBsAg-negative, anti-HBc-positive, of whom 62 were recruited and monitored for a median of 48 (4-104) weeks. The 2-year cumulative HBV DNA detectability rate was 40.8%, occurring at a median of 44 (8-100) weeks. Multivariate analysis showed that age 50 years (P 5 0.004, hazard ratio 5 8.2) and chronic graft-versus-host disease (P 5 0.010, hazard ratio 5 5.3) were significantly associated with HBV reactivation. Other clinical parameters, including baseline antibody to HBsAg status, serial changes in antibody to HBsAg levels, and donor serology, were not associated with HBV reactivation. Patients <50 years old and without chronic graft-versus-host disease, compared with the remaining patient cohort, had a significantly lower 2-year cumulative HBV reactivation rate (5.6% versus 65.0%, P 5 0.004). Entecavir successfully suppressed HBV DNA to undetectable levels, with no cases developing biochemical hepatitis. Conclusion: HBsAg-negative, anti-HBc-positive patients had a high rate of HBV reactivation after allogeneic HSCT, with determinants of HBV reactivation including age 50 years and chronic graft-versus-host disease; treatment strategies based on these parameters may prevent HBV reactivation and subsequent complications. (ClinicalTrials.gov identifier NCT01481649.) (HEPATOLOGY 2017;65:1451-1461.
I
n patients with prior exposure to hepatitis B virus (HBV), viral reactivation is a potentially fatal complication during the administration of immunosuppressive therapy. (1) Patients who are hepatitis B surface antigen (HBsAg)-positive have the highest risk, ranging 14%-78%, with a mortality rate of 5%-22%. (2) Prophylactic antiviral therapy for HBsAgpositive patients receiving immunosuppressive therapy is effective at preventing HBV reactivation and hence reducing HBV-related morbidity and mortality.
HBV reactivation is also possible in HBsAg-negative individuals who are positive for antibody to hepatitis B core antigen (anti-HBc), which indicates past HBV infection. (4) These individuals may have apparently resolved acute HBV infection (5) or chronic HBV infection with HBsAg seroclearance but persistently low levels of viral replication and transcription. (6) HBV reactivation is still possible with immunosuppressive therapies, particularly those containing the B celldepleting antibody rituximab. A recent prospective study showed a 2-year cumulative reactivation rate of 41.5% in HBsAg-negative, anti-HBc-positive lymphoma patients receiving rituximab-containing chemotherapeutic regimens. (7) HBV reactivation has been reported in HBsAgpositive carriers undergoing allogeneic or autologous hematopoietic stem cell transplantation (HSCT), (8) but its risk in HBsAg-negative, anti-HBc-positive patients has not been clearly defined. The frequency of HBV reactivation in HBsAg-negative, anti-HBc-positive patients after HSCT might range from 2.6% to 42.9%. (9) (10) (11) (12) (13) These variable frequencies were related to the lack of regular monitoring after HSCT or using HBsAg seroreversion, a relatively late clinical event, to define HBV reactivation. (9, 10, 13) Factors postulated to predispose to HBV reactivation include absence of antibody to HBsAg (anti-HBs) in either HSCT recipients (10) or donors, (8, 12) occurrence of graft-versus-host disease (GVHD), (8) and post-HSCT immunosuppression. (12) However, none of these factors have been evaluated prospectively.
An estimated 2 billion people worldwide have been infected by HBV, (14) with the seroprevalence of antiHBc in East Asia ranging from 13.5% to 68.2%. (15) (16) (17) With the increasing performance of HSCT, (18) the incidence of HBV reactivation post-HSCT in patients previously infected by HBV is expected to surge. To address this important clinical problem, we conducted a prospective study to determine the frequency and factors associated with HBV reactivation, as defined by standard criteria, in HBsAg-negative, anti-HBc-positive patients undergoing allogeneic HSCT.
Patients and Methods

PATIENTS
We conducted a 3-year (September 2011 to November 2014) prospective observational study to define the risk of HBV reactivation in HBsAgnegative, anti-HBc-positive patients undergoing allogeneic HSCT. Inclusion criteria included consecutive Asian patients 18 years who were HBsAg-negative, anti-HBc-positive undergoing allogeneic HSCT at our center. Exclusion criteria included patients with detectable HBV DNA (10 IU/mL) prior to HSCT, HSCT from HBsAg-positive donors, prior history of anti-HBV therapy, and concomitant chronic liver diseases due to chronic hepatitis C and D infection, Wilson's disease, autoimmune hepatitis, primary biliary cirrhosis, and significant intake of alcohol (men, 30 g/ day; women, 20 g/day). All data were censored in February 2015, with a target monitoring period of 2 years.
Informed consent was obtained from all participants. The study was approved by the University of Hong Kong-Hong Kong West Cluster Institutional Review Board, in accordance with the Declaration of Helsinki. This study was registered under ClinicalTrials.gov (identifier NCT-01481649) and HKClinicalTrials.com (identifier HKCTR-1422).
HSCT-RELATED PROCEDURES
Donors included siblings or voluntary unrelated donors. Details of conditioning regimens are given in the Supporting Information. GVHD prophylaxis comprised cyclosporine (1.5 mg/kg Q12H, day -1 onward) and methotrexate (15 mg/m 2 on day 1; 10 mg/m 2 on days 3, 6, and 11) for sibling donors, with the addition of mycophenolate mofetil (500 mg twice daily, days 0-60, and 250 mg twice daily, days 61-90) for voluntary unrelated donors. Serum cyclosporine levels were maintained at 200-250 nmol/L for sibling HSCT and 250-300 nmol/L for voluntary unrelated donor HSCT. In the absence of GVHD, cyclosporine and mycophenolate mofetil were tapered from day 100 onward and eventually discontinued.
Clinical diagnosis of acute and chronic GVHD was based on the National Institutes of Health consensus guidelines (19) and confirmed histologically whenever feasible. When the diagnostic criteria were not fulfilled due to a lack of histological confirmation, empirical treatment might still be initiated based on clinical features and the discretion of the attending physician. Treatment and response assessment of GVHD followed standard criteria. (20, 21) 
MONITORING OF HBV STATUS
Serum HBsAg, anti-HBc, and anti-HBs were measured according to the manufacturer's instructions (Abbott Laboratories, Chicago, IL), with the lowest limit of detection of serum anti-HBs at 10 mIU/mL. Quantification of serum HBsAg was performed with the Elecsys HBsAg II assay (Roche Diagnostics, Gmbh, Mannheim, Germany; lowest limit of detection, 0.05 IU/mL). Serum HBV DNA levels were measured with Abbott RealTime HBV (Abbott Molecular, Des Plaines, IL; lowest limit of detection, 10 IU/mL). These parameters were evaluated every 4 weeks post-HSCT until week 104, and every 3 months thereafter. A designated research assistant was tasked to remind patients of their scheduled blood draws and to ensure that all specimens were regularly collected. Once HBV reactivation as defined by detectable HBV DNA (10 IU/mL) occurred, the nucleoside analogue entecavir (0.5 mg/day) was commenced as recommended. (22) Patients were then monitored every 1-3 months, with entecavir continued until at least 12 months after cessation of all immunosuppressive therapy.
ENDPOINTS
The primary endpoint was HBV reactivation (HBV DNA 10 IU/mL), regardless of liver biochemistry and HBsAg status. Secondary endpoints included overall survival, HBsAg positivity, and changes in serum alanine aminotransferase (ALT) and anti-HBs levels at reactivation.
SAMPLE SIZE
We compared the HBV reactivation rates between baseline anti-HBs-positive and anti-HBs-negative patients, using our previous study involving rituximabcontaining chemotherapy as reference. (7) Based on our previous results, we surmised that the reactivation rates in anti-HBs-positive and anti-HBs-negative patients were 34% and 68%, respectively. With an alpha risk of 5% and 85% power, 60 patients were required. Allowing a 3%-5% dropout rate, we aimed at recruiting 62 patients.
STATISTICAL ANALYSES
Continuous variables were expressed as medians (range). The Mann-Whitney U test was used for comparing continuous variables, and the chi-squared test, or the Fisher's exact test where appropriate, was used to compare categorical variables. The cumulative rate of HBV reactivation was calculated with the KaplanMeier method, and differences were calculated by the log-rank method. Data were censored if HBV reactivation or mortality occurred.
The impact of the following parameters on HBV reactivation was analyzed by univariate analysis: age (<50 versus 50 years), gender, human leukocyte antigen status (fully matched versus not fully matched), hematopoietic stem cell source (bone marrow versus peripheral blood), conditioning (myeloablative versus nonmyeloablative), baseline ALT (less than versus greater than or equal to upper reference level), baseline albumin (less than versus greater than or equal to upper reference level), baseline anti-HBs (10 versus 50 versus 100 mIU/mL), change of anti-HBs level (baseline versus end of follow-up), donor anti-HBs (< versus 10 IU/mL), donor anti-HBc status, occurrence of GVHD, use of high-dose steroids (defined as prednisolone 1 mg/kg or more versus low-dose or no steroids), and cumulative doses of immunosuppressants used. Because the cumulative dose of immunosuppressants increased with time, an alternative relation between HBV reactivation and the dosagetime profile of corticosteroids, cyclosporine, and mycophenolate mofetil was further analyzed. Specifically, the cumulative dose of each immunosuppressant every 4 weeks was included in the Cox proportional hazard regression model as a univariate time-dependent covariate. In addition, as a sensitivity analysis, the potential impact of dosage adjustment of immunosuppressants every 4 weeks was quantitatively tested similarly by including the usage of immunosuppressants as a timedependent indicator variable and the change in dosage every 4 weeks as a time-dependent covariate. Parameters with P < 0.10 were then included in a multivariate Cox proportional hazards regression analysis. A twosided P value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL) and R version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results
PATIENTS
Patient disposition is shown in Fig. 1 . Two hundred and ninety-seven consecutive allogeneic HSCTs were performed during the study period, with 85 (28.7%) HSCT recipients being HBsAg-negative, anti-HBcpositive. After excluding patients who were already on antiviral therapy (n 5 12), had HBsAg-positive donors (n 5 7), had detectable HBV DNA at baseline (n 5 3), or were positive for anti-HCV (n 5 1), 62 patients were recruited (Table 1 ). The median duration of follow-up was 56 (range 4-176) weeks. Within our 2-year target monitoring period, the median duration of Continuous variables expressed as median (range).
*Anti-HBc status of 10 unrelated donors from overseas bone marrow registries not available. Quantification of anti-HBs among unrelated donors was also not available. † Diagnosis based on the National Institutes of Health consensus. (18) One patient developed chronic GVHD after HBV reactivation. The occurrence of this chronic GVHD was excluded from our analysis. ‡ Methylprednisolone dosage converted to prednisolone in the ratio 4:5. § Including thalidomide, imatinib, sirolimus, tacrolimus, basiliximab, and anti-thymocyte globulin. k Maximum follow-up duration was 104 weeks. Follow-up was censored if mortality occurred. observation was 48 (range 4-104) weeks, with 18 patients (29.0%) reaching the target observation duration of 104 weeks.
Twenty patients (32.3%) died after a median of 28 (range 4-96) weeks after HSCT (hematological disease recurrence, n 5 10; sepsis, n 5 5; veno-occlusive disease, n 5 3; posttransplant lymphoproliferative disease, n 5 1; lung cancer, n 5 1). Twenty-three (37.1%) patients developed GVHD (acute n 5 11, chronic n 5 6, acute and chronic n 5 6) ( Table 1) .
FIG. 2.
Cumulative rates of HBV reactivation among (A) all patients, (B) patients with versus patients without chronic GVHD, (C) patients 50 years old versus patients <50 years old, and (D) patients stratified by development of chronic GVHD and/or age. #For Kaplan-Meier calculation, data censored at both HBV reactivation and mortality. *Inclusive of patients monitored after HBV reactivation.
CUMULATIVE RATE OF HBV REACTIVATION
The cumulative rates of HBV reactivation at 6 months, 1 year, and 2 years were 5.6%, 17.7%, and 40.8%, respectively (Fig. 2A) . Thirteen patients (20.9%) at a median age of 53.4 (30.8-60.9) years developed HBV reactivation at a median of 44 (range 8-100) weeks after HSCT (Table 2 ). All patients had received immunosuppressive therapy, including cyclosporine (n 5 13), mycophenolate mofetil (n 5 12), corticosteroids (n 5 9), and anti-thymocyte globulin (n 5 1). HBV reactivation occurred during immunosuppressive therapy in all but 1 patient. In patient 7 ( Table 2 ) HBV reactivation occurred 24 weeks after cessation of immunosuppressive therapy. There were no cases of HBV reactivation among the small number of patients (n 5 9) followed up beyond the 2-year monitoring period to a maximum of 176 weeks.
The median HBV DNA level at HBV reactivation was 24.8 (range 14.6-428) IU/mL. Twelve patients (92.3%) remained HBsAg-negative at reactivation. One patient seroreverted to HBsAg positivity at a low level of 0.77 IU/mL. The median serum ALT at reactivation was not different from that at baseline (37 versus 40 U/L, P 5 0.383).
OUTCOME OF ANTIVIRAL THERAPY FOR HBV REACTIVATION
With commencement of entecavir, all 13 patients achieved undetectable HBV DNA levels after a median of 6 (range 4-10) weeks. The only patient with positive HBsAg at HBV reactivation had HBsAg seroclearance after 8 months of treatment. No patients developed biochemical hepatitis or hepatic decompensation.
CLINICAL FACTORS ASSOCIATED WITH HBV REACTIVATION
Univariate analysis (Table 3) showed that HBV reactivation was significantly associated with GVHD (P 5 0.013), especially chronic GVHD (P 5 0.020), and age 50 years (P 5 0.031). On multivariate analysis (Table 3) , age 50 years (P 5 0.004, hazard ratio 5 8.2, 95% confidence interval 2.0-33.3) and chronic GVHD (P 5 0.010, hazard ratio 5 5.3, 95% confidence interval 1.5-18.5) remained significantly related to HBV reactivation. Among patients with steroid therapy (n 5 32), the median time to steroid commencement was 7.7 (range 2.9-41.3) weeks. No association existed between the timing of steroid therapy and HBV reactivation (P 5 0.245).
The serial changes in anti-HBs levels are shown in Supporting Fig. S1 . The median declines in anti-HBs levels among patients with and without HBV reactivation were 36 (range 317 to -270) IU/mL and 16 (range 789 to -399) IU/mL (P 5 0.823), respectively. Decline in anti-HBs levels had no association with HBV reactivation (Table 3 , P 5 0.691).
IMPACT OF CHRONIC GVHD AND AGE ON HBV REACTIVATION
Patients with GVHD (acute and/or chronic) had a significantly higher 2-year cumulative HBV reactivation rate when compared to patients without GVHD (79.5% versus 20.8%; P 5 0.007) (Supporting Fig. S2A ). However, HBV reactivation was not significantly different in patients with and without acute GVHD (2-year cumulative rate, 65.4% versus 27.2%; (19) One patient developed chronic GVHD after HBV reactivation. The occurrence of this chronic GVHD was excluded from our analysis. k High-dose steroids defined as prednisolone 1 mg/kg or more. Methylprednisolone dosage converted to prednisolone in the ratio 4:5. ¶ Cyclosporine was prescribed to all allogeneic HSCT recipients as part of GVHD prophylaxis. # Including thalidomide, imatinib, sirolimus, tacrolimus, basiliximab, and anti-thymocyte globulin. P 5 0.076) (Supporting Fig. S2B ). Instead, HBV reactivation was significantly more frequent in patients with than without chronic GVHD (cumulative rates at 6 months, 9.1% versus 4.5%; 12 months, 42.7% versus 10.5%; 24 months, 78.4% versus 28.6%; P 5 0.013) (Fig. 2B) . Age 50 years, when compared with age <50 years, was associated with a significant increase in cumulative HBV reactivation rate (61.8% versus 24.8% at 2 years, P 5 0.021, Fig. 2C ). Among chronic GVHD patients developing HBV reactivation (n 5 6), viral reactivation occurred at a median of 5.7 (range 1.9-15.6) months after the occurrence of chronic GVHD.
The cumulative rates of HBV reactivation as stratified by the development of chronic GVHD and age are shown in Fig. 2D . For patients aged <50 years with no chronic GVHD, the 2-year cumulative rate of HBV reactivation was only 5.6%, which was significantly lower than the 65.0% in the remaining patients (P 5 0.004). In fact, only 1 out of 28 patients (3.6%) aged <50 years without chronic GVHD developed HBV reactivation.
Discussion
This prospective study showed a high cumulative rate of HBV reactivation of 40.8% in HBsAgnegative, anti-HBc-positive Asian patients undergoing allogeneic HSCT. Two important determinants for HBV reactivation, chronic GVHD and age 50 years, were defined.
Previous reports of HBV reactivation during HSCT were all retrospective analyses. (9) (10) (11) (12) (13) Because of selection bias, disparate monitoring strategies, and different definitions of viral reactivation, the exact incidence and risk factors for HBV reactivation during HSCT have not been clearly determined. In this study, we recruited consecutive patients. Moreover, patients were prospectively monitored at 4-weekly intervals, ensuring an accurate determination of the exact timing of HBV reactivation. Most importantly, we adopted a clear-cut definition of HBV reactivation as detectability of HBV DNA with a quantitative polymerase chain reaction assay. Appearance of serum HBV DNA is the first stage of HBV reactivation, which if untreated might be followed by HBV-related hepatitis and possibly hepatic failure.
(1,23) Therefore, we started antiviral treatment on detecting HBV DNA as internationally recommended, (22) effectively suppressing viral replication at an early stage and hence preventing the further development of biochemical or clinical hepatitis. Our results support the empirical recommendation of starting antiviral treatment at the time of HBV DNA detection. (22) While using a low HBV DNA level cutoff might lead to the overdiagnosing and overtreatment of HBV reactivation, without the development of recipient HBV immunity, (13) the successful prevention of any HBV-related morbidity in the current study means that our data are robust enough to formulate a safe management strategy for HBsAg-negative, antiHBc-positive patients undergoing allogeneic HSCT.
The average age of HBsAg seroclearance in patients with chronic HBV infection is approximately 50 years. (6, 24, 25) Therefore, it is conceivable that many HBsAg-negative, anti-HBc-positive patients 50 years old who have prior HBsAg seroclearance might in fact have chronic HBV infection. These patients have HBV persisting at low transcriptional and replicative levels and are therefore more likely to have viral reactivation with suppression of immunity. (6) This might explain why age 50 years was an important determinant of HBV reactivation after HSCT.
Furthermore, this study prospectively identified the relationship between GVHD and HBV reactivation in HBsAg-negative, anti-HBc-positive patients (Table  3) . Patients with GVHD are much more immunocompromised than patients without GVHD for two important reasons. Firstly, they receive more immunosuppressive therapy to curb the clinical manifestations of GVHD. Secondly, GVHD delays proper reconstitution of the immune system for up to 12-18 months and is hence itself potently immunosuppressive. (26) In the initial 3 months after HSCT, patients with or without acute GVHD both received quite intensive immunosuppression, and this might explain why acute GVHD only insignificantly increased the rate of HBV reactivation. However, in the later stages after HSCT, patients with chronic GVHD would typically receive much more immunosuppressive therapy than patients without GVHD, who would have tapering of immunosuppressants. To define whether the impact of GVHD on HBV reactivation might merely reflect an increase in the use of immunosuppressants, we performed a sensitivity analysis examining the effect of dosage adjustment of immunosuppressants on HBV reactivation. With no significant effect demonstrated (Table 3) , the increased risk of HBV reactivation might therefore be related instead to the delay in immune reconstitution consequent on chronic GVHD. (26) Universal prophylactic antiviral therapy can prevent HBV reactivation in HBsAg-negative, anti-HBc-positive individuals undergoing immunosuppression, (27) but it might not be a cost-effective approach in HBVendemic regions with a high anti-HBc seroprevalence. (15) (16) (17) One can consider dichotomizing management strategies based on the patient's age and occurrence of GVHD (Fig. 3) . For patients aged 50 years, regardless of whether or not chronic GVHD occurs, given their high risk of HBV reactivation (61.8% in 2 years), prophylactic antiviral therapy should be considered in centers without the resources for frequent HBV DNA monitoring; and its clinical efficacy should be validated prospectively in future studies. For patients <50 years old and without chronic GVHD, the risk of HBV reactivation is low (5.6% in 2 years) and regular monitoring, shown by our study to be an effective strategy, might be more cost-effective. If chronic GVHD develops in these patients, the risk of HBV reactivation is substantially increased and antiviral therapy becomes warranted.
We have not studied autologous HSCT, which might have different risk factors for HBV reactivation. Factors found to be predictive of HBV reactivation in prior retrospective studies (e.g., donor anti-HBs negativity (12) ) might require further evaluation in studies with a larger sample size. Our study cohort only included Asian patients. Validation studies in other populations are needed, especially because anti-HBc positivity in populations of European descent usually indicates exposure to HBV in adulthood, with a much smaller chance of chronicity and continuing viral replication and therefore reactivation. This is opposed to Asian populations who are more frequently exposed to HBV at a young age and become chronic carriers, (28) with therefore a correspondingly higher risk of viral reactivation. Prospective data beyond 2 years will be needed as late HBV reactivation can occur. (9, 10, 12) Because our study participants were on immunosuppression during the majority of follow-up, such longterm data will help to determine the risk of reactivation after the tapering off of immunosuppression.
In conclusion, there was a high rate of HBV reactivation among HBsAg-negative, anti-HBc-positive patients undergoing allogeneic HSCT. Age 50 years and chronic GVHD were important determinants. Without these two risk factors, the incidence of HBV reactivation was low. Baseline anti-HBs status and serial changes in anti-HBs levels were not associated with reactivation. Entecavir therapy commenced once HBV DNA became detectable successfully suppressed viral replication and completely prevented HBVrelated complications.
